United States securities and exchange commission logo

                 March 30, 2022

       Tim Mayleben
       Chief Executive Officer
       Landos Biopharma, Inc.
       1800 Kraft Drive, Suite 216
       Blacksburg, Virginia 24060

                                                        Re: Landos Biopharma,
Statement on Form S-3
                                                            Filed March 24,
                                                            File No. 333-263836

       Dear Mr. Mayleben:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

              Please contact Michael Davis at 202-551-4385 or Laura Crotty at
202-551-7614 with any


                 Division of Corporation Finance

                 Office of Life Sciences
       cc:                                              Eric Blanchard